Luye Pharma Group (HKEX: 02186) announced the successful completion of a US pharmacokinetic (PK) bridging study of LY03015, its investigational dual-mechanism compound for tardive dyskinesia (TD), clearing a procedural prerequisite for potential US regulatory submissions. The trial enrolled its first subject in April 2026 and reached completion within approximately three and a half months.
LY03015 is designed to simultaneously inhibit vesicular monoamine transporter 2 (VMAT2), reducing dopamine release implicated in the involuntary movements of TD, while activating the sigma-1 receptor (Sigma-1R), a target associated with neuroprotection and modulation of dopaminergic signaling. Luye Pharma describes it as the first investigational compound to combine both mechanisms.
The bridging study was an open-label, single-dose, parallel-group Phase I trial comparing pharmacokinetics, safety, and tolerability in healthy Chinese and Caucasian adult subjects. Completion of the study removes a key regulatory requirement for using Chinese clinical data to support US development, although Luye has not disclosed the pharmacokinetic results.
The completion follows a June 2026 announcement that LY03015's Phase II trial in China for TD met its primary endpoint, with the company reporting a 76.5% response rate. That China dataset, combined with the now-completed US bridging data, positions Luye Pharma to advance regulatory discussions with the FDA, though the company has not disclosed a timeline for an investigational new drug application or new drug application filing.